Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study
CONCLUSION: Our results from clinical practice suggest that RDV and SARS-CoV-2 mAb therapies elicit worse outcomes in hematological patients than those reported for high-risk population in clinical trials.PMID:37656351 | DOI:10.1007/s43440-023-00519-8 (Source: Pharmacological Reports)
Source: Pharmacological Reports - September 1, 2023 Category: Drugs & Pharmacology Authors: Juan Vicente-Valor Carmen Rodr íguez-González Mar ía Ferris-Villanueva Esther Chamorro-de-Vega Rosa Romero-Jim énez Daniel G ómez-Costas Sergio Herrero-Bermejo Francisco Tejerina-Picado Santiago Osorio-Prendes Gillen Oarbeascoa-Royuela Ana Herranz-Al Source Type: research
Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study
CONCLUSION: Our results from clinical practice suggest that RDV and SARS-CoV-2 mAb therapies elicit worse outcomes in hematological patients than those reported for high-risk population in clinical trials.PMID:37656351 | DOI:10.1007/s43440-023-00519-8 (Source: Pharmacological Reports)
Source: Pharmacological Reports - September 1, 2023 Category: Drugs & Pharmacology Authors: Juan Vicente-Valor Carmen Rodr íguez-González Mar ía Ferris-Villanueva Esther Chamorro-de-Vega Rosa Romero-Jim énez Daniel G ómez-Costas Sergio Herrero-Bermejo Francisco Tejerina-Picado Santiago Osorio-Prendes Gillen Oarbeascoa-Royuela Ana Herranz-Al Source Type: research
Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study
CONCLUSION: Our results from clinical practice suggest that RDV and SARS-CoV-2 mAb therapies elicit worse outcomes in hematological patients than those reported for high-risk population in clinical trials.PMID:37656351 | DOI:10.1007/s43440-023-00519-8 (Source: Pharmacological Reports)
Source: Pharmacological Reports - September 1, 2023 Category: Drugs & Pharmacology Authors: Juan Vicente-Valor Carmen Rodr íguez-González Mar ía Ferris-Villanueva Esther Chamorro-de-Vega Rosa Romero-Jim énez Daniel G ómez-Costas Sergio Herrero-Bermejo Francisco Tejerina-Picado Santiago Osorio-Prendes Gillen Oarbeascoa-Royuela Ana Herranz-Al Source Type: research
Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α < sub > 2 < /sub > -adrenoceptor and trace amine-associated receptor 1 ligand
CONCLUSIONS: The precise sequence of molecular events within the organism, linking the impact of 4-OH-Guanabenz on α2A-adrenoceptor and TAAR1 with weight reduction and the amelioration of metabolic disturbances, remains an unresolved matter necessitating further investigation. Undoubtedly, the fact that 4-OH-Guanabenz is a metabolite of a well-known drug has considerable importance, which is beneficial from an economic point of view and towards its further development as a drug candidate.PMID:37624466 | DOI:10.1007/s43440-023-00518-9 (Source: Pharmacological Reports)
Source: Pharmacological Reports - August 25, 2023 Category: Drugs & Pharmacology Authors: Magdalena Kota ńska Monika Marcinkowska Kamil J Kuder Maria Walczak Marek Bednarski Agata Siwek Marcin Ko łaczkowski Source Type: research
Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α < sub > 2 < /sub > -adrenoceptor and trace amine-associated receptor 1 ligand
CONCLUSIONS: The precise sequence of molecular events within the organism, linking the impact of 4-OH-Guanabenz on α2A-adrenoceptor and TAAR1 with weight reduction and the amelioration of metabolic disturbances, remains an unresolved matter necessitating further investigation. Undoubtedly, the fact that 4-OH-Guanabenz is a metabolite of a well-known drug has considerable importance, which is beneficial from an economic point of view and towards its further development as a drug candidate.PMID:37624466 | DOI:10.1007/s43440-023-00518-9 (Source: Pharmacological Reports)
Source: Pharmacological Reports - August 25, 2023 Category: Drugs & Pharmacology Authors: Magdalena Kota ńska Monika Marcinkowska Kamil J Kuder Maria Walczak Marek Bednarski Agata Siwek Marcin Ko łaczkowski Source Type: research
Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α < sub > 2 < /sub > -adrenoceptor and trace amine-associated receptor 1 ligand
CONCLUSIONS: The precise sequence of molecular events within the organism, linking the impact of 4-OH-Guanabenz on α2A-adrenoceptor and TAAR1 with weight reduction and the amelioration of metabolic disturbances, remains an unresolved matter necessitating further investigation. Undoubtedly, the fact that 4-OH-Guanabenz is a metabolite of a well-known drug has considerable importance, which is beneficial from an economic point of view and towards its further development as a drug candidate.PMID:37624466 | DOI:10.1007/s43440-023-00518-9 (Source: Pharmacological Reports)
Source: Pharmacological Reports - August 25, 2023 Category: Drugs & Pharmacology Authors: Magdalena Kota ńska Monika Marcinkowska Kamil J Kuder Maria Walczak Marek Bednarski Agata Siwek Marcin Ko łaczkowski Source Type: research
Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α < sub > 2 < /sub > -adrenoceptor and trace amine-associated receptor 1 ligand
CONCLUSIONS: The precise sequence of molecular events within the organism, linking the impact of 4-OH-Guanabenz on α2A-adrenoceptor and TAAR1 with weight reduction and the amelioration of metabolic disturbances, remains an unresolved matter necessitating further investigation. Undoubtedly, the fact that 4-OH-Guanabenz is a metabolite of a well-known drug has considerable importance, which is beneficial from an economic point of view and towards its further development as a drug candidate.PMID:37624466 | DOI:10.1007/s43440-023-00518-9 (Source: Pharmacological Reports)
Source: Pharmacological Reports - August 25, 2023 Category: Drugs & Pharmacology Authors: Magdalena Kota ńska Monika Marcinkowska Kamil J Kuder Maria Walczak Marek Bednarski Agata Siwek Marcin Ko łaczkowski Source Type: research
Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α < sub > 2 < /sub > -adrenoceptor and trace amine-associated receptor 1 ligand
CONCLUSIONS: The precise sequence of molecular events within the organism, linking the impact of 4-OH-Guanabenz on α2A-adrenoceptor and TAAR1 with weight reduction and the amelioration of metabolic disturbances, remains an unresolved matter necessitating further investigation. Undoubtedly, the fact that 4-OH-Guanabenz is a metabolite of a well-known drug has considerable importance, which is beneficial from an economic point of view and towards its further development as a drug candidate.PMID:37624466 | DOI:10.1007/s43440-023-00518-9 (Source: Pharmacological Reports)
Source: Pharmacological Reports - August 25, 2023 Category: Drugs & Pharmacology Authors: Magdalena Kota ńska Monika Marcinkowska Kamil J Kuder Maria Walczak Marek Bednarski Agata Siwek Marcin Ko łaczkowski Source Type: research
Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α < sub > 2 < /sub > -adrenoceptor and trace amine-associated receptor 1 ligand
CONCLUSIONS: The precise sequence of molecular events within the organism, linking the impact of 4-OH-Guanabenz on α2A-adrenoceptor and TAAR1 with weight reduction and the amelioration of metabolic disturbances, remains an unresolved matter necessitating further investigation. Undoubtedly, the fact that 4-OH-Guanabenz is a metabolite of a well-known drug has considerable importance, which is beneficial from an economic point of view and towards its further development as a drug candidate.PMID:37624466 | DOI:10.1007/s43440-023-00518-9 (Source: Pharmacological Reports)
Source: Pharmacological Reports - August 25, 2023 Category: Drugs & Pharmacology Authors: Magdalena Kota ńska Monika Marcinkowska Kamil J Kuder Maria Walczak Marek Bednarski Agata Siwek Marcin Ko łaczkowski Source Type: research
Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies
Pharmacol Rep. 2023 Aug 21. doi: 10.1007/s43440-023-00515-y. Online ahead of print.ABSTRACTThe evaluation of dolutegravir based on available preclinical and clinical studies reveals a risk of central nervous system (CNS) disorders associated with long-term use of the drug. The available literature on the pharmacokinetics of the drug, including its penetration of the blood-brain barrier, was reviewed, as well as clinical trials assessing the incidence of adverse effects in the CNS and the frequency of its discontinuation. This paper also summarizes the impact of factors affecting the occurrence of CNS disorders and indicate...
Source: Pharmacological Reports - August 22, 2023 Category: Drugs & Pharmacology Authors: Alicja Jakimiuk Agnieszka Piechal Alicja Wierci ńska-Drapało Alicja Nowaczyk Dagmara Mirowska-Guzel Source Type: research
Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies
Pharmacol Rep. 2023 Aug 21. doi: 10.1007/s43440-023-00515-y. Online ahead of print.ABSTRACTThe evaluation of dolutegravir based on available preclinical and clinical studies reveals a risk of central nervous system (CNS) disorders associated with long-term use of the drug. The available literature on the pharmacokinetics of the drug, including its penetration of the blood-brain barrier, was reviewed, as well as clinical trials assessing the incidence of adverse effects in the CNS and the frequency of its discontinuation. This paper also summarizes the impact of factors affecting the occurrence of CNS disorders and indicate...
Source: Pharmacological Reports - August 22, 2023 Category: Drugs & Pharmacology Authors: Alicja Jakimiuk Agnieszka Piechal Alicja Wierci ńska-Drapało Alicja Nowaczyk Dagmara Mirowska-Guzel Source Type: research
Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies
Pharmacol Rep. 2023 Aug 21. doi: 10.1007/s43440-023-00515-y. Online ahead of print.ABSTRACTThe evaluation of dolutegravir based on available preclinical and clinical studies reveals a risk of central nervous system (CNS) disorders associated with long-term use of the drug. The available literature on the pharmacokinetics of the drug, including its penetration of the blood-brain barrier, was reviewed, as well as clinical trials assessing the incidence of adverse effects in the CNS and the frequency of its discontinuation. This paper also summarizes the impact of factors affecting the occurrence of CNS disorders and indicate...
Source: Pharmacological Reports - August 22, 2023 Category: Drugs & Pharmacology Authors: Alicja Jakimiuk Agnieszka Piechal Alicja Wierci ńska-Drapało Alicja Nowaczyk Dagmara Mirowska-Guzel Source Type: research
A re-consideration of neural/receptor mechanisms in chemotherapy-induced nausea and vomiting: current scenario and future perspective
Pharmacol Rep. 2023 Aug 16. doi: 10.1007/s43440-023-00514-z. Online ahead of print.ABSTRACTThe neural mechanisms and the receptors behind the course of chemotherapy-induced nausea and vomiting (CINV) are well described and considered mechanistically multifactorial, whereas the neurobiology of nausea is not completely understood yet. Some of the anti-neoplastic medications like cisplatin result in biphasic vomiting response. The acute phase of vomiting is triggered mainly via the release of serotonin from the enterochromaffin (EC) cells in the gastrointestinal tract (GIT) and results in stimulation of dorsal vagal complex (...
Source: Pharmacological Reports - August 16, 2023 Category: Drugs & Pharmacology Authors: Ihsan Ullah Muhammad Ayaz Source Type: research
Metabolomics-directed nanotechnology in viral diseases management: COVID-19 a case study
Pharmacol Rep. 2023 Aug 16. doi: 10.1007/s43440-023-00517-w. Online ahead of print.ABSTRACTThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently regarded as the twenty-first century's plague accounting for coronavirus disease 2019 (COVID-19). Besides its reported symptoms affecting the respiratory tract, it was found to alter several metabolic pathways inside the body. Nanoparticles proved to combat viral infections including COVID-19 to demonstrate great success in developing vaccines based on mRNA technology. However, various types of nanoparticles can affect the host metabolome. Considering the i...
Source: Pharmacological Reports - August 16, 2023 Category: Drugs & Pharmacology Authors: Marwa O El-Derany Diana M F Hanna John Youshia Enas Elmowafy Mohamed A Farag Samar S Azab Source Type: research
A re-consideration of neural/receptor mechanisms in chemotherapy-induced nausea and vomiting: current scenario and future perspective
Pharmacol Rep. 2023 Aug 16. doi: 10.1007/s43440-023-00514-z. Online ahead of print.ABSTRACTThe neural mechanisms and the receptors behind the course of chemotherapy-induced nausea and vomiting (CINV) are well described and considered mechanistically multifactorial, whereas the neurobiology of nausea is not completely understood yet. Some of the anti-neoplastic medications like cisplatin result in biphasic vomiting response. The acute phase of vomiting is triggered mainly via the release of serotonin from the enterochromaffin (EC) cells in the gastrointestinal tract (GIT) and results in stimulation of dorsal vagal complex (...
Source: Pharmacological Reports - August 16, 2023 Category: Drugs & Pharmacology Authors: Ihsan Ullah Muhammad Ayaz Source Type: research
